Načítá se...
Direct-acting antivirals for the treatment of chronic hepatitis C in patients with chronic kidney disease
All-oral, direct-acting antivirals (DAAs) have significantly improved the efficacy and safety of chronic hepatitis C (CHC) treatment but their effectiveness and safety among patients with chronic kidney disease (CKD) remains poorly understood. Our aim was to assess the efficacy and safety of DAAs fo...
Uloženo v:
| Vydáno v: | Therap Adv Gastroenterol |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
SAGE Publications
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5076774/ https://ncbi.nlm.nih.gov/pubmed/27803742 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756283X16665254 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|